Clinical Trials
26 trialsNCT03878199 2026-04-24
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Ohio State University Comprehensive Cancer Center
Phase 1/2 Terminated
NCT03862157 2026-03-11
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05123365 2026-03-10
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
University of California, Irvine
Phase 1/2 Recruiting
NCT05499013 2025-12-19
SLN
Silence Therapeutics plc
Phase 1/2 Active not recruiting
NCT00816413 2023-08-14
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Phase 1/2 Withdrawn
NCT04051307 2023-07-13
Dual Vaccine Trial in Myeloproliferative Neoplasms
Herlev Hospital
Phase 1/2 Completed
NCT04354727 2022-07-12
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Ascentage Pharma Group Inc.
Phase 1/2 Withdrawn
NCT01423851 2022-03-09
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
NS Pharma, Inc.
Phase 1/2 Completed
NCT01787552 2020-04-15
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Novartis
Phase 1/2 Completed
NCT00669578 2019-12-30
CC-4047 in Treating Patients With Myelofibrosis
Mayo Clinic
Phase 1/2 Completed
NCT01901432 2019-07-30
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
Italfarmaco
Phase 1/2 Completed
NCT00509899 2018-03-12
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Incyte Corporation
Phase 1/2 Completed
NCT01193699 2018-01-30
PEGINVERA
AOP Orphan Pharmaceuticals AG
Phase 1/2 Completed
NCT00245037 2017-09-27
Bu Flu TBI
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT00448357 2017-07-17
LCCC0510
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT01167166 2017-06-26
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Traws Pharma, Inc.
Phase 1/2 Completed
NCT00052520 2017-03-29
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01298934 2015-03-06
LBH589 (Panobinostat) for the Treatment of Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT00668421 2014-11-26
CEP-701 (Lestaurtinib) in Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT00003619 2013-06-26
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00003406 2013-03-26
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00823524 2013-02-20
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Asan Medical Center
Phase 1/2 Completed
NCT01101412 2013-02-15
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00745550 2012-04-20
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
S*BIO
Phase 1/2 Completed
NCT00049634 2010-09-16
Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00054340 2010-05-14
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
Fred Hutchinson Cancer Center
Phase 1/2 Completed